Healthcare workers at Vajira Hospital diagnosed with LTBI who have had close contact with patients diagnosed with pulmonary tuberculosis during the past 3 months and have undergone treatment with the 3HP regimen Healthcare workers, Latent tuberculosis infection, Tuberculosis preventive therapy, NAT2 genotype
Conditions
Interventions
HCWs with no or minimal ADEs during the 12 weeks until completing the full course of treatment,TPT was discontinued during treatment due to serious ADEs (defined as death, life-threatening, hospitaliz
Treatment,Treatment
Complete treatment,Incomplete treatment
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: Healthcare workers with LTBI at Vajira Hospital who have had significant close contact with patients diagnosed with pulmonary tuberculosis during the 3 months before the index case began treatment, meeting one of the following criteria: 1.Contact with contagious TB for at least 8 hours per day in the same location. 2.Cumulative contact of 120 hours or more per month with contagious TB patients. 3.Exposure to poorly ventilated areas where contagious tuberculosis patients were present and where adequate personal protective equipment (PPE) was not used
Exclusion criteria
Exclusion criteria: 1. HCWs with a history of contact with patients diagnosed with drug-resistant tuberculosis, viral hepatitis infection, human immunodeficiency virus infection, abnormal liver function tests, related to high access alcohol, active cancer on treatment, unstable myocardial ischemia, heart failure grade 3 or 4, other serious illness, potentially serious drug interactions, history of allergic reaction to isoniazid or rifapentine 2. HCWs deny to participate 3. Incomplete data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse drug events at 3 months (end of the treatment) Dose onset of any ADEs, ADE severity, Fever, Fatigue, Headache, Myalgia, Flu-like syndrome, Nausea, vomiting, Diarrhea, Hepatotoxicity, Peripheral neuropathy, Cutaneous reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| NAT2 genotypes at 3 months (end of the treatment) or stop treatment Rapid acetylator, Intermediate acetylator, Slow acetylator | — |
Countries
Thailand
Contacts
Public ContactPipu Tavornshevin
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Outcome results
None listed